|Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy|
M Chesi, GM Matthews, VM Garbitt, SE Palmer, J Shortt, M Lefebure, ...
Blood, The Journal of the American Society of Hematology 120 (2), 376-385, 2012
|BET-bromodomain inhibitors engage the host immune system and regulate expression of the immune checkpoint ligand PD-L1|
SJ Hogg, SJ Vervoort, S Deswal, CJ Ott, J Li, LA Cluse, PA Beavis, ...
Cell reports 18 (9), 2162-2174, 2017
|Oncogenes in cell survival and cell death|
J Shortt, RW Johnstone
Cold Spring Harbor perspectives in biology 4 (12), a009829, 2012
|An intact immune system is required for the anticancer activities of histone deacetylase inhibitors|
AC West, SR Mattarollo, J Shortt, LA Cluse, AJ Christiansen, MJ Smyth, ...
Cancer research 73 (24), 7265-7276, 2013
|CDK9 inhibition by dinaciclib potently suppresses Mcl-1 to induce durable apoptotic responses in aggressive MYC-driven B-cell lymphoma in vivo|
GP Gregory, SJ Hogg, LM Kats, E Vidacs, AJ Baker, O Gilan, M Lefebure, ...
Leukemia 29 (6), 1437-1441, 2015
|ADAMTS13 antibody depletion by bortezomib in thrombotic thrombocytopenic purpura|
MB Jake Shortt, SS Opat
The New England journal of medicine 368 (1), 90, 2013
|Differentiation therapy for the treatment of t (8; 21) acute myeloid leukemia using histone deacetylase inhibitors|
M Bots, I Verbrugge, BP Martin, JM Salmon, M Ghisi, A Baker, K Stanley, ...
Blood, The Journal of the American Society of Hematology 123 (9), 1341-1352, 2014
|Thalidomide-analogue biology: immunological, molecular and epigenetic targets in cancer therapy|
J Shortt, AK Hsu, RW Johnstone
Oncogene 32 (36), 4191-4202, 2013
|Combination therapy targeting ribosome biogenesis and mRNA translation synergistically extends survival in MYC-driven lymphoma|
JR Devlin, KM Hannan, N Hein, C Cullinane, E Kusnadi, PY Ng, ...
Cancer discovery 6 (1), 59-70, 2016
|Combined inhibition of PI3K-related DNA damage response kinases and mTORC1 induces apoptosis in MYC-driven B-cell lymphomas|
J Shortt, BP Martin, A Newbold, KM Hannan, JR Devlin, AJ Baker, R Ralli, ...
Blood 121 (15), 2964-2974, 2013
|A chemical probe toolbox for dissecting the cancer epigenome|
J Shortt, CJ Ott, RW Johnstone, JE Bradner
Nature Reviews Cancer 17 (3), 160, 2017
|NKT cell adjuvant-based tumor vaccine for treatment of myc oncogene-driven mouse B-cell lymphoma|
SR Mattarollo, AC West, K Steegh, H Duret, C Paget, B Martin, ...
Blood, The Journal of the American Society of Hematology 120 (15), 3019-3029, 2012
|The CDK9 inhibitor dinaciclib exerts potent apoptotic and antitumor effects in preclinical models of MLL-rearranged acute myeloid leukemia|
A Baker, GP Gregory, I Verbrugge, L Kats, JJ Hilton, E Vidacs, EM Lee, ...
Cancer research 76 (5), 1158-1169, 2016
|Adjuvant rituximab causes prolonged hypogammaglobulinaemia following autologous stem cell transplant for non-Hodgkin's lymphoma|
J Shortt, A Spencer
Bone marrow transplantation 38 (6), 433-436, 2006
|The mTORC1 inhibitor everolimus prevents and treats Eμ-Myc lymphoma by restoring oncogene-induced senescence|
M Wall, G Poortinga, KL Stanley, RK Lindemann, M Bots, CJ Chan, ...
Cancer discovery 3 (1), 82-95, 2013
|AIDS-related plasmablastic lymphoma of the oral cavity associated with an IGH/MYC translocation–treatment with autologous stem-cell transplantation in a patient with severe …|
MA Dawson, AP Schwarer, C McLean, P Oei, LJ Campbell, E Wright, ...
Haematologica 92 (1), e11-e12, 2007
|Manipulation of B-cell responses with histone deacetylase inhibitors|
M Waibel, AJ Christiansen, ML Hibbs, J Shortt, SA Jones, I Simpson, ...
Nature communications 6 (1), 1-12, 2015
|E6AP ubiquitin ligase regulates PML-induced senescence in Myc-driven lymphomagenesis|
K Wolyniec, J Shortt, E de Stanchina, Y Levav-Cohen, O Alsheich-Bartok, ...
Blood, The Journal of the American Society of Hematology 120 (4), 822-832, 2012
|BET inhibition induces apoptosis in aggressive B-cell lymphoma via epigenetic regulation of BCL-2 family members|
SJ Hogg, A Newbold, SJ Vervoort, LA Cluse, BP Martin, GP Gregory, ...
Molecular cancer therapeutics 15 (9), 2030-2041, 2016
|Assessment of the urgency and deferability of transfusion to inform emergency blood planning and triage: the Bloodhound prospective audit of red blood cell use|
J Shortt, MN Polizzotto, N Waters, M Borosak, M Moran, M Comande, ...
Transfusion 49 (11), 2296-2303, 2009